SCHEMBL23780218

SCHEMBL23780218

Cc1cccc(C2CCN(C(=O)OC(C)(C)C)CC2O)c1C

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 5/20 0.45
USP30 Q70CQ3 3/20 0.42
JAK2 O60674 2/20 0.41
JAK3 P52333 1/20 0.41
PTK2 Q05397 1/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
STS P08842 1/20 0.41
JAK1 P23458 1/20 0.41
PTPN2 P17706 1/20 0.40
PTPN1 P18031 1/20 0.40
PTPN6 P29350 1/20 0.40
KDM4E B2RXH2 1/20 0.40
PKM P14618 1/20 0.40
TGFBR1 P36897 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3062560 0.83 GPR119 (0.48) GPR119USP30JAK2JAK1PTPN2
SCHEMBL3788083 0.82 GPR119 (0.48) GPR119USP30JAK2MAPTJAK1
SCHEMBL21775336 0.82 GPR119 (0.49) GPR119USP30JAK2STSJAK1
SCHEMBL21748714 0.82 GPR119 (0.49) GPR119USP30JAK2STSJAK1
SCHEMBL5161271 0.82 GPR119 (0.49) GPR119USP30JAK2STSJAK1
SCHEMBL21748713 0.82 GPR119 (0.49) GPR119USP30JAK2STSJAK1
SCHEMBL21855588 0.82 GPR119 (0.52) GPR119LMNATP53MAPTSTS
SCHEMBL31150633 0.82 GPR119 (0.52) GPR119LMNATP53MAPTSTS
SCHEMBL407256 0.79 GPR119 (0.54) GPR119USP30JAK2JAK3PTK2
SCHEMBL2242108 0.79 GPR119 (0.54) GPR119USP30JAK2JAK3PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3873464-B1 NOVEL SUBSTITUTED PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS MERCK SHARP & DOHME LLC (US) 2025-07-30 EP disclosed
US-12091405-B2 Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors MERCK SHARP & DOHME LLC (US) 2024-09-17 US disclosed
US-20210395240-A1 NOVEL SUBSTITUTED PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-12-23 US disclosed
EP-3873464-A1 NOVEL SUBSTITUTED PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2021-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210395240-A1 NOVEL SUBSTITUTED PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS IDO1, IDO2, TPH1 GPR119 356/4885USP30 2021/4885JAK2 1126/4885
US-12091405-B2 Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors IDO1, IDO2, KYNU GPR119 519/4885USP30 2217/4885JAK2 1163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.